310 related articles for article (PubMed ID: 20583092)
1. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.
Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ
Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092
[TBL] [Abstract][Full Text] [Related]
2. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
3. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
4. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
6. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
8. Non-lymphoid cancer after liver transplantation.
Frezza EE; Fung JJ; van Thiel DH
Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
11. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
[TBL] [Abstract][Full Text] [Related]
14. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation.
Glanville AR; Aboyoun CL; Morton JM; Plit M; Malouf MA
J Heart Lung Transplant; 2006 Aug; 25(8):928-34. PubMed ID: 16890113
[TBL] [Abstract][Full Text] [Related]
16. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
Opelz G; Döhler B;
Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
[TBL] [Abstract][Full Text] [Related]
17. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.
Kelly DM; Emre S; Guy SR; Miller CM; Schwartz ME; Sheiner PA
Cancer; 1998 Sep; 83(6):1237-43. PubMed ID: 9740091
[TBL] [Abstract][Full Text] [Related]
18. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
19. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.
Herrero JI; Lorenzo M; Quiroga J; Sangro B; Pardo F; Rotellar F; Alvarez-Cienfuegos J; Prieto J
Liver Transpl; 2005 Jan; 11(1):89-97. PubMed ID: 15690541
[TBL] [Abstract][Full Text] [Related]
20. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
